FDA panel votes against approval of eteplirsen for DMD

FDA panel votes against approval of eteplirsen for DMD

(HealthDay)—The drug eteplirsen should not be approved for treatment of Duchenne muscular dystrophy, a U.S. Food and Drug Administration advisory panel said Monday.

There are currently no drugs to treat the disease. Patients, parents, and doctors insist the drug prolongs the ability of boys with Duchenne muscular dystrophy to walk long after they would normally be in wheelchairs, The New York Times reported. However, the FDA's panel of outside experts said from drug maker Sarepta Therapeutics did not meet the agency's requirements for well controlled studies necessary for approval. The vote was 7-3, with three abstentions.

The study submitted by Sarepta included only 12 patients and did not have adequate placebo control, The Times reported. The panel members found conflict between patient testimony and FDA rules. "Based on all I heard, the drug definitely works, but the question was framed differently," said Bruce Ovbiagele, M.D., chairman of neurology at the Medical University of South Carolina in Charleston, who voted against approval, The Times reported.

The FDA's decision on whether to approve eteplirsen will be made by May 26. The agency does not have to follow the recommendations of its advisory panels.


Explore further

New muscular dystrophy drug's chances for approval improve

More information: More Information

Copyright © 2016 HealthDay. All rights reserved.

Citation: FDA panel votes against approval of eteplirsen for DMD (2016, April 27) retrieved 17 September 2019 from https://medicalxpress.com/news/2016-04-fda-panel-votes-eteplirsen-dmd.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
3 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more